Product Images Cleocin Phosphate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 26 images provide visual information about the product associated with Cleocin Phosphate NDC 0009-0902 by Pharmacia & Upjohn Company Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Pfizer, a renowned pharmaceutical company, distributes their products through Pharmacia & Upjohn Company LLC, which is a subsidiary of Pfizer Inc. The address of the company is in New York, NY 10017. The purpose of this text is likely to provide information about the company and their distribution network.*
This is a label of a Pfizer product produced by its subsidiary, Pharmacia & Upjohn Company LLC, and distributed to hospitals. The product's name is not available.*
This is a description of a medication in 25 single doses contained in a 2mL vial. The medication is clindamycin injection, USP and each 2mL contains 150mg/mL of the medication. It is intended for intramuscular or intravenous use and requires a prescription. The medication should be stored in a temperature range of 20 to 25 degrees Celsius and should not be refrigerated. For dosage and usage instructions, refer to the accompanying prescribing information.*
This is a description of Cleocin Phosphate, which is an injectable medication used by Intramuscular or Intravenous route. Each vial of Cleocin Phosphate contains 150 mg/mL of Clindamycin Injection. It is stored at a controlled room temperature of 20°C to 25°C (68°F to 77°F) and should not be refrigerated. The dosage and use of the medicine should be taken as per the accompanying prescribing information. The text also includes some numerical codes and the manufacturer's address.*
Each 4 mL vial of Cleocin Phosphate contains clindamycin phosphate equivalent to 600 g for intramuscular or intravenous use of clindamycin. This medication is available by prescription only and comes in a single-dose container with an NDC of 0009-0775-20. It should be stored at controlled room temperature (68° to 77°F) and should not be refrigerated. For dosage and usage instructions, please refer to the accompanying prescribing information. The concentration of this clindamycin injection is 150 mg/mL.*
Cleocin Phosphate® is a clindamycin injection medication used for intramuscular or intravenous use. The dosage and usage should be consulted in accompanying prescribing information. The medication comes in a 900 mg/6 mL vial and contains clindamycin hydrochloride as the active ingredient. The medication can be stored at room temperature, up to 77°F.*
Cleocin Phosphate is a clindamycin injection, USP, useful for intramuscular or intravenous use. It is not intended for direct infusion; instead, aliquots should be dispensed through a dispensing device or infusion fluids using aseptic techniques. The storage temperature is controlled at 20° to 25°C (68° to 77°F), and it should not be refrigerated. The dosage and use should follow the prescription information. It contains 150 mg of cindamycin phosphate per mL, along with disodium edetate, sodium hydroxide, hydrochloric acid, and benzyl alcohol as a preservative. The vial should be discarded within 24 hours after initial entry. This pharmacy bulk package is distributed by Pharmacy & Upjohn Co, a division of Pfizer Inc., NY, NY 10017. The product's date and time entered can be found at the bottom of the text.*
Cleocin Phosphate is a clindamycin injection solution presented in 5- 60mL pharmacy bulk packages, offering 9,000mg/60mL dosage. It is designed for intramuscular or intravenous use only and is not recommended for direct infusion. Store at a controlled temperature of 20° to 25°C. It contains clindamycin phosphate equivalent to 150 mg of clindamycin and other appropriate solutions. For more information on administration or usage, see the accompanying prescribing information. In the case of intravenous usage, it must be diluted before use. The pH of the injection may be modified by the use of sodium hydroxide and/or hydrochloric acid.*
Cleocin Phosphate is a medication containing clindamycin used for intravenous use only. The product should be stored at controlled room temperature and not be refrigerated. Each 4 mL contains lindamycin phosphates equivalent to 600 mg of clindamycin. The accompanying dosage and use information should also be reviewed. The product is distributed under a registered trademark called ADD-Vantage by Hospira. The product is available in a 150 mg/mL strength and should only be used with the ADD-Vantage diluent container. The NDC number for this medication is NDC0009-3124-01.*
Cleocin Phosphate® is a medication containing Clindamycin for intravenous use. It is available in a 25mL single dose vial with a concentration of 150mg/mL. The medication should be stored at controlled room temperature between 20°C to 25°C and should not be refrigerated. Dosage and usage instructions should be obtained from the accompanying prescription. Users should take care when handling it and always use it with ADD-Vantage® and other appropriate measures, as the medication contains Clindamycin. The text seems to be a product label or instruction sheet.*
This is information about a medication with the brand name Cleocin Phosphate. The medication is available in injectable form and contains the active ingredient clindamycin. The recommended method of administration is intravenous injection. The medication comes with an ADD-Vantage diluent container and should only be used with this container. Dosage and usage instructions are not provided in the text.*
This is a product information containing details about Cleocin Phosphate, which is an intravenous injection used for medical purposes and distributed by Pramaca Lponco. The text includes information about the dosage, storage, and warnings, including not using Cleocin Phosphate without a prescription. The text also contains some numbers and product codes but lacks readability due to errors.*
This is a description for Cleocin Phosphate 1V Solution, used for clindamycin injection. It contains 300 mg of clindamycin and 25 g of dextrose hydrous, USP, and must not be used in series connections or for rapid injection. It is manufactured for Pize Inc by Baxter Healthcare Corporation and should be stored at room temperature. The recommended dosage and additional information can be found in the accompanying prescribing information. Cautions include not adding supplementary medication and checking for minute leaks by squeezing the bag.*
This is a description of Cleocin Phosphate®, which is a clindamycin injection in 1v solution for intravenous use. It comes in a 50mL container and contains 600mg clindamycin and 2.5g dextrose hydrous. It is nonpyrogenic and sterile, and it is recommended to be stored at room temperature. This medication should not be used for rapid injection or IV push, and it should not be used in series connections or with supplementary medication. The container is to be checked for minute leaks and solution clarity. It is manufactured by Baxter Healthcare Corporation and distributed by Pharmacia & Upjohn, which is a division of Pfizer Inc in New York.*
This is a description for a package of Clindamycin injection in the form of 2 boxes of 1201 NDC 0009-3375.01. Each box contains 50 ml single-dose containers of Cleocin Phosphate® Iv Solution in 5% Dextrose. It is recommended to avoid temperatures exceeding 30°C and not to use the solution unless the liquid is clear. The storage temperature is 25°C. It is cautioned not to add other medication to the solution, and it must not be used in series connections. It is also noted that the solution should not be used for rapid injection or IV push.*
Cleocin Phosphate is a clindamycin injection contained in a single dose container with 900 mg/50mL strength to be used for intravenous use only. Clindamycin phosphate in each 50mL solution with 2.5g dextrose hydrous, USP, and 2mg edetate disodium dihydrate, USP added. It is sterilized, nonpyrogenic, and recommended to be stored at 25°C. CLEOCIN PHOSPHATE I is a registered trademark of Pharmacia & Upjohn Company. Baxter International Inc's Galaxy is its registered trademark. The solution must not be used in series connections and not for rapid injection or IV push without examining for leaks and solution clarity. Users must check the accompanying prescribing information and precautiously avoid adding supplementary medication.*
This is a description of a medication called Cleocin Phosphate IV Solution in a single dose container with 21250 m (milliliters) volume. The container is made of plastic and is sterile and non-pyrogenic. It is not recommended to add any supplementary medication, and it should not be used in series connections. The solution should be checked for minute leaks by squeezing the bag firmly. It contains clindamycin phosphate equivalent to 900 mg of clindamycin and 2.5 g of dextrose hydrous. The pH is adjusted with sodium hydroxide and/or hydrochloric acid, and it is distributed by Pharmacia & Upjohn Co. The recommended storage temperature is room temperature, and it should be kept away from temperatures above 30°C. The dosage and use of the solution must follow the prescribing information, and it should not be taken by rapid injection or IV push. The solution is a registered trademark of Pharmacia & Upjohn Company and the container, of Baxter International Inc. The container is manufactured for Pfizer Inc by Baxter Healthcare Corporation.*
This is a description of a medication product called Cleocin Phosphate, which is a clindamycin injection for intravenous use only. Each 2 mL contains 300 mg of clindamycin and should be stored at controlled room temperature (20° to 25°C), not refrigerated. It can only be used with the ADD-Vantage diluent container. The text also includes some uninterpretable characters, making it unclear if the correctly recognized the content.*
Cleocin Phosphate® is an injection medication containing clindamycin and comes in a 150 mg/mL strength. The labeling contains a warning to use the medication carefully as it can cause severe side effects and requires the addition of an electrolyte solution before use. The packaging lists a specific dosing amount of 252 mL. There is also mention of a product called Vantage Vile and a registered trademark symbol. The rest of the text is difficult to read due to errors.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.